# Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study

> **NCT03088267** · PHASE3 · COMPLETED · sponsor: **Tris Pharma, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** amphetamine extended-release oral suspension, 2.5 mg/mL
- **DRUG:** Placebo extended-release oral suspension

## Key facts

- **NCT ID:** NCT03088267
- **Lead sponsor:** Tris Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-11
- **Primary completion:** 2017-02-25
- **Final completion:** 2017-10-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03088267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03088267, "Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03088267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*